About This Deal

Danaher Corporation acquired Pall Corporation for approximately $13.8 billion ($127.20 per share cash; total enterprise value including assumed debt and net of acquired cash), a transaction completed in August 2015, structured as all cash (merger).

Pall Corporation operates in Life Sciences (filtration), is based in Port Washington, New York, USA, had revenue of about $2.8 billion consolidated revenue in fiscal year ended July 2014 ($1.5 billion Life Sciences segment, $1.3 billion Industrial segment). Pall is a leading global provider of filtration, separation and purification solutions that remove contaminants or separate substances from a variety of solids, liquids and gases, serving the broad spectrum of life sciences and industry.

Pall is a highly attractive business, with approximately 75% recurring revenues, mid-single digit organic growth and a solid margin profile. Its best-in-class technology and broad, technically-advanced solutions make it the premier brand in the filtration industry, strengthening Danaher's life-sciences position in the high-growth biopharmaceutical market.

approximately 75% recurring revenues; biopharma exposure in the Life Sciences segment Danaher Life Sciences segment

Deal Terms

Acquirer
Danaher Corporation
Target
Pall Corporation
Value
Approximately $13.8 billion ($127.20 per share cash; total enterprise value including assumed debt and net of acquired cash)
Date
August 2015
Type
Full acquisition
Status
Ready

Transaction Details

Target HQ
Port Washington, New York, USA
Segment
Life Sciences (filtration)
Structure
All cash (merger)
Target revenue
$2.8 billion consolidated revenue in fiscal year ended July 2014 ($1.5 billion Life Sciences segment, $1.3 billion Industrial segment)
Announced
May 13, 2015
Closed
August 31, 2015

In Their Words

Pall is a highly attractive business, with approximately 75% recurring revenues, mid-single digit organic growth and a solid margin profile. Pall will provide us a leading business with significant runway for expansion and strengthens our life sciences position in the strategically-attractive, high-growth biopharmaceutical market.Thomas P. Joyce, Jr., President and CEO, Danaher Corporation

Advisors

Advisory firms were not disclosed for this transaction.

Related Deals & Entities

Sources: Press release ↗ · SEC filing ↗ · Last updated July 8, 2026

See how VectorShift works for your firm

Request Demo